Total records found: 774
Hide HeadlineShow Headline
Sort
Release Time Stock Code Stock Short Name Document
Release Time: 06/10/2026 17:17 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 (69KB)
Release Time: 30/09/2026 17:13 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [List of Directors and their Role and Function]
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS (38KB)
Release Time: 30/09/2026 17:10 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Re-election or Appointment of Director subject to Shareholders' Approval / Change in...
More
Announcements and Notices - [Re-election or Appointment of Director subject to Shareholders' Approval / Change in Directors or of Important Executive Functions or Responsibilities / Change of Nomination Committee Member]
]
(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES (47KB)
Release Time: 24/09/2026 16:53 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Financial Statements/ESG Information - [Interim/Half-Year Report]
INTERIM REPORT 2026 (3MB)
Release Time: 23/09/2026 16:58 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - COLLABORATION AND LICENSE AGREEMENT WITH AMBERSTONE FOR TWO T CELL ENGAGER PRODUCTS (43KB)
Release Time: 11/09/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR 120 MG (1.7 ML) PER VIAL STRENGTH OF BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) HAS BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) (41KB)
Release Time: 07/09/2026 12:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Miscellaneous]
VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE LIST OF ELIGIBLE SECURITIES OF HONG KONG STOCK CONNECT (43KB)
Release Time: 02/09/2026 17:38 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026 (70KB)
Release Time: 25/08/2026 18:24 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Next Day Disclosure Returns - [Others]
Next Day Disclosure Returns (85KB)
Release Time: 21/08/2026 19:31 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Miscellaneous]
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX (36KB)
Release Time: 21/08/2026 19:24 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Interim Results / Change in Registered Address or Office, Registered Place of Business in HK...
More
Announcements and Notices - [Interim Results / Change in Registered Address or Office, Registered Place of Business in HK or Agent for Service of Process in HK]
]
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG (1MB)
Release Time: 17/08/2026 08:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANDOZ (50KB)
Release Time: 04/08/2026 16:54 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026 (70KB)
Release Time: 03/08/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Date of Board Meeting]
DATE OF BOARD MEETING (34KB)
Release Time: 31/07/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING PD-L1) IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (46KB)
Release Time: 30/07/2026 17:25 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS IN CHINESE MAINLAND (41KB)
Release Time: 17/07/2026 22:26 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Share Scheme]
GRANTS OF OPTIONS AND RSUS (76KB)
Release Time: 16/07/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE GLOBAL FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ANTI-PD-1 HUMANIZED MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH MULTIPLE RESECTED SOLID TUMORS IN CHINESE MAINLAND (42KB)
Release Time: 10/07/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY OR HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMOURS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (44KB)
Release Time: 08/07/2026 17:24 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC HUMAN-MURINE MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC) IN CHINESE MAINLAND (42KB)
Release Time: 06/07/2026 17:11 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026 (70KB)
Release Time: 30/06/2026 17:14 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/ METASTATIC SOLID TUMORS IN CHINESE MAINLAND (41KB)
Release Time: 25/06/2026 18:20 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN THE UNITED STATES HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR HLX13 (RECOMBINANT ANTI-CTLA-4 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA (HCC) (58KB)
Release Time: 25/06/2026 18:02 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE EUROPEAN COMMISSION (EC) HAS APPROVED A NEW INDICATION FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY), IN COMBINATION WITH CHEMOTHERAPY INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CARCINOMA (sqNSCLC) (45KB)
Release Time: 17/06/2026 17:18 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (40KB)
Release Time: 17/06/2026 17:11 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - HANBEIYOU (PERTUZUMAB INJECTION) PASSING GMP COMPLIANCE INSPECTION (46KB)
Release Time: 16/06/2026 17:14 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE PHASE 2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) FOR NEOADJUVANT THERAPY OF NON-SMALL CELL LUNG CANCER (NSCLC) APPROVED TO COMMENCE IN AUSTRALIA (47KB)
Release Time: 16/06/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) HAS MET THE PRIMARY STUDY ENDPOINT (49KB)
Release Time: 11/06/2026 17:27 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Next Day Disclosure Returns - [Others]
Next Day Disclosure Returns (84KB)
Release Time: 09/06/2026 18:09 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT TREATMENT FOR GASTRIC CANCER HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) (50KB)
Release Time: 05/06/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF PEMBROLIZUMAB HLX17 (RECOMBINANT HUMANISED ANTI-PD-1 MONOCLONAL ANTIBODY INJECTION) IN PATIENTS WITH MULTIPLE RESECTED SOLID TUMOURS IN THE UNITED STATES (42KB)
Release Time: 03/06/2026 16:54 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026 (69KB)
Release Time: 29/05/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED HANBEIYOU (PERTUZUMAB INJECTION) FOR THE NEOADJUVANT/ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER AND FOR THE TREATMENT OF METASTATIC BREAST CANCER (41KB)
Release Time: 28/05/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2/3 CLINICAL STUDY OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) AS MONOTHERAPY OR IN COMBINATION WITH PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANIZED MONOCLONAL ANTIBODY INJECTION) VERSUS DOCETAXEL FOR THE TREATMENT OF ADVANCED/METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE PRIOR TREATMENT HAS FAILED IN CHINESE MAINLAND (48KB)
Release Time: 26/05/2026 16:59 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 2/3 CLINICAL STUDY COMPARING PIMURTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANIZED MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND CHEMOTHERAPY VERSUS PLACEBO IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) OR PEMBROLIZUMAB AND CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) IN CHINESE MAINLAND (44KB)
Release Time: 26/05/2026 16:51 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF HLX15-SC (RECOMBINANT ANTI-CD38 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION-SUBCUTANEOUS INJECTION) FOR FIRST-LINE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) IN CHINESE MAINLAND (59KB)
Release Time: 22/05/2026 21:47 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) RECEIVED POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) (45KB)
Release Time: 22/05/2026 16:44 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE FC FUSION PROTEIN) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS IN CHINESE MAINLAND (41KB)
Release Time: 21/05/2026 17:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN AN EU COUNTRY (SPAIN) HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2 CLINICAL STUDY OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (45KB)
Release Time: 21/05/2026 17:22 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1xCD3xCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER ADVANCED SOLID TUMORS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA (40KB)
Release Time: 21/05/2026 17:13 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMORS HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (40KB)
Release Time: 19/05/2026 18:31 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Results of AGM]
POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 19 MAY 2026 (44KB)
Release Time: 13/05/2026 17:07 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE TARGETING EGFR AND C-MET) FOR THE TREATMENT OF ADVANCED/METASTATIC SOLID TUMORS HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA (40KB)
Release Time: 13/05/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX97 (KAT6A/B SMALL MOLECULE INHIBITOR) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS IN CHINESE MAINLAND (41KB)
Release Time: 10/05/2026 18:23 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC HUMAN-MONOCLONAL ANTIBODY INJECTION) FOR METASTATIC COLORECTAL CANCER (mCRC) APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) (40KB)
Release Time: 10/05/2026 18:07 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - EUROPEAN COMMISSION (EC) APPROVED TWO NEW INDICATIONS FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) (46KB)
Release Time: 07/05/2026 16:49 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 (69KB)
Release Time: 04/05/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTICENTER PHASE 2/3 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) AS MONOTHERAPY OR IN COMBINATION WITH PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANIZED MONOCLONAL ANTIBODY INJECTION) FOR ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) HAS BEEN PERMITTED TO COMMENCE IN JAPAN (45KB)
Release Time: 30/04/2026 16:39 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX3901 INJECTION (DLL3xDLL3xCD3xCD28 TETRA-SPECIFIC ANTIBODY) FOR THE TREATMENT OF PATIENTS WITH ADVANCED SMALL CELL LUNG CANCER OR NEUROENDOCRINE CARCINOMA IN CHINESE MAINLAND (41KB)
Release Time: 28/04/2026 19:47 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - EUROPEAN COMMISSION (EC) APPROVED HLX11 (PERTUZUMAB, TRADE NAME IN THE UNITED STATES AND EUROPE: POHERDY) FOR TREATMENTS INCLUDING NEOADJUVANT/ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER AND METASTATIC BREAST CANCER (42KB)
Release Time: 24/04/2026 18:07 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE PHASE 2/3 CLINICAL TRIAL OF PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANISED MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND CHEMOTHERAPY VERSUS PLACEBO IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) OR PEMBROLIZUMAB AND CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) HAS BEEN APPROVED TO COMMENCE IN AUSTRALIA (41KB)
Release Time: 24/04/2026 17:54 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Proxy Forms
PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 19 MAY 2026 (OR ANY ADJOURNMENT THEREOF) (60KB)
Release Time: 24/04/2026 17:49 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Notice of AGM / Closure of Books or Change of Book Closure Period]
NOTICE OF ANNUAL GENERAL MEETING (69KB)
Release Time: 24/04/2026 17:42 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Circulars - [General Mandate / Explanatory Statement for Repurchase of Shares / Other]
(1) ANNUAL REPORT 2025 (2) BOARD REPORT 2025 (3) BOARD OF SUPERVISORS REPORT 2025 (4) FINAL ACCOUNTS REPORT 2025 (5) PROFIT DISTRIBUTION PROPOSAL 2025 (6) RE-APPOINTMENT OF AUDITORS (7) REMUNERATIONS OF THE FULL-TIME EXECUTIVE DIRECTOR FOR THE YEAR 2025 (8) GRANT OF GENERAL MANDATE TO ISSUE SHARES (9) GRANT OF GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF AGM (136KB)
Release Time: 24/04/2026 17:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Financial Statements/ESG Information - [Annual Report]
ANNUAL REPORT 2025 (7MB)
Release Time: 24/04/2026 17:23 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Financial Statements/ESG Information - [Environmental, Social and Governance Information/Report]
2025 Environmental, Social and Governance Report (5MB)
Release Time: 24/04/2026 17:16 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Circulars - [Other]
Notification Letter and Reply Form to Non-Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (811KB)
Release Time: 24/04/2026 17:08 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Circulars - [Other]
Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (783KB)
Release Time: 17/04/2026 20:40 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Share Scheme]
GRANTS OF OPTIONS AND RSUS (72KB)
Release Time: 14/04/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - PHASE 1 CLINICAL TRIAL APPLICATION OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ANTI-EGFR CHIMERIC HUMAN-MONOCLONAL ANTIBODY INJECTION) FOR METASTATIC COLORECTAL CANCER (mCRC) APPROVED BY NMPA (40KB)
Release Time: 10/04/2026 16:50 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST SUBJECT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF PERTUZUMAB AND TRASTUZUMAB INJECTION (SUBCUTANEOUS INJECTION) BIOSIMILAR HLX319 IN CHINESE MAINLAND (43KB)
Release Time: 09/04/2026 17:50 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTARY APPLICATIONS FOR INDICATION EXPANSION OF HANLIKANG (RITUXIMAB INJECTION) APPROVED BY NMPA (63KB)
Release Time: 08/04/2026 18:21 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 (69KB)
Release Time: 01/04/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATIONS FOR THE PHASE 1 CLINICAL TRIALS OF PERTUZUMAB AND TRASTUZUMAB INJECTION (SUBCUTANEOUS INJECTION) BIOSIMILAR HLX319 WERE APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (40KB)
Release Time: 31/03/2026 17:58 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLXTE-HAase02 (RECOMBINANT HUMAN HYALURONIDASE INJECTION) APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (39KB)
Release Time: 30/03/2026 17:51 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) RECEIVED POSITIVE OPINIONS FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) (46KB)
Release Time: 26/03/2026 16:48 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1B/2 CLINICAL STUDY OF HLX701 (RECOMBINANT HUMAN SIRPa-IgG4 Fc FUSION PROTEIN INJECTION) IN COMBINATION WITH CETUXIMAB AND CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED COLORECTAL CANCER IN CHINESE MAINLAND (75KB)
Release Time: 20/03/2026 18:16 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Final Results]
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 (988KB)
Release Time: 20/03/2026 18:11 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ANTI-PD-1 HUMANIZED MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF MULTIPLE SOLID TUMORS WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (40KB)
Release Time: 20/03/2026 18:04 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Change in Company Secretary / Change in Registered Address or Office, Registered Place of...
More
Announcements and Notices - [Change in Company Secretary / Change in Registered Address or Office, Registered Place of Business in HK or Agent for Service of Process in HK]
]
CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORISED REPRESENTATIVE (40KB)
Release Time: 20/03/2026 18:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Continuing Connected Transaction]
CONTINUING CONNECTED TRANSACTIONS - PROMOTIONAL SERVICES AGREEMENT (65KB)
Release Time: 16/03/2026 17:44 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF PIMURUTAMAB HLX07 (RECOMBINANT ANTI-EGFR HUMANISED MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) (41KB)
Release Time: 09/03/2026 16:37 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE FC FUSION PROTEIN) FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) (40KB)
Release Time: 09/03/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX3901 INJECTION (DLL3xDLL3xCD3xCD28 TETRA-SPECIFIC ANTIBODY) FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (40KB)
Release Time: 05/03/2026 17:20 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR CLINICAL TRIAL OF HLX97 (KAT6A/B SMALL MOLECULE INHIBITOR) FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (39KB)
Release Time: 04/03/2026 18:08 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 (73KB)
Release Time: 03/03/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Date of Board Meeting]
DATE OF BOARD MEETING (34KB)
Release Time: 27/02/2026 22:22 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - PERTUZUMAB BIOSIMILAR HLX11 (RECOMBINANT ANTI-HER2 DOMAIN II HUMANIZED MONOCLONAL ANTIBODY INJECTION) RECEIVED POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) (41KB)
Release Time: 27/02/2026 22:17 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN THE PHASE 2/3 CLINICAL STUDY OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HLX87 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING HER2) FOR FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE RECURRENT OR METASTATIC BREAST CANCER (BC) IN CHINESE MAINLAND (45KB)
Release Time: 24/02/2026 16:52 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - AMENDMENTS TO LICENSE AGREEMENTS WITH ABBOTT AND KGBIO FOR HANSIZHUANG (46KB)
Release Time: 16/02/2026 12:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX15-SC (RECOMBINANT ANTI-CD38 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION-SUBCUTANEOUS INJECTION) FOR THE TREATMENT OF MULTIPLE MYELOMA WAS APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) (58KB)
Release Time: 12/02/2026 16:48 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX15-SC (RECOMBINANT ANTI-CD38 FULLY HUMAN MONOCLONAL ANTIBODY INJECTION-SUBCUTANEOUS INJECTION) FOR THE TREATMENT OF MULTIPLE MYELOMA APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) (57KB)
Release Time: 11/02/2026 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE 1B/2 CLINICAL STUDY OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH HLX07 (RECOMBINANT ANTI-EGFR HUMANISED MONOCLONAL ANTIBODY INJECTION) OR HANSIZHUANG (SERPLULIMAB INJECTION) IN PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER IN CHINESE MAINLAND (47KB)
Release Time: 05/02/2026 16:41 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - LICENSE AGREEMENT WITH EISAI IN RESPECT OF HANSIZHUANG (42KB)
Release Time: 04/02/2026 16:45 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Next Day Disclosure Returns - [Others]
Next Day Disclosure Returns (86KB)
Release Time: 04/02/2026 16:41 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF THE H SHARE FULL CIRCULATION (40KB)
Release Time: 03/02/2026 18:05 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 (69KB)
Release Time: 27/01/2026 17:26 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH HLX07 (RECOMBINANT ANTI-EGFR HUMANISED MONOCLONAL ANTIBODY INJECTION) AND HANSIZHUANG (SERPLULIMAB INJECTION) FOR THE TREATMENT OF ADVANCED SOLID TUMOURS WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (47KB)
Release Time: 20/01/2026 16:57 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR A PHASE 1B/2 CLINICAL TRIAL OF HLX701 (RECOMBINANT HUMAN SIRPa - IgG4 Fc FUSION PROTEIN INJECTION) IN COMBINATION WITH CETUXIMAB AND CHEMOTHERAPY FOR THE TREATMENT OF ADVANCED COLORECTAL CANCER APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (73KB)
Release Time: 19/01/2026 22:28 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY (72KB)
Release Time: 16/01/2026 16:30 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Inside Information]
INSIDE INFORMATION ANNOUNCEMENT - ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY (48KB)
Release Time: 13/01/2026 16:51 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION (BLA) FOR HANBEITAI (BEVACIZUMAB INJECTION) HAS BEEN ACCEPTED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) (40KB)
Release Time: 06/01/2026 17:17 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 (66KB)
Release Time: 31/12/2025 18:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Results of EGM/SGM]
POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 31 DECEMBER 2025 (41KB)
Release Time: 31/12/2025 17:54 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Continuing Connected Transaction]
CONTINUING CONNECTED TRANSACTIONS (110KB)
Release Time: 29/12/2025 17:44 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ANTIBODY) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMOURS IN CHINESE MAINLAND (41KB)
Release Time: 19/12/2025 17:00 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ANTI-PD-1 HUMANIZED MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF MULTIPLE SOLID TUMORS WAS APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) (40KB)
Release Time: 12/12/2025 16:46 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ADJUVANT TREATMENT FOR GASTRIC CANCER HAS BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) AND HAS BEEN GRANTED PRIORITY REVIEW (43KB)
Release Time: 09/12/2025 17:14 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - APPLICATIONS FOR PHASE 2/3 CLINICAL TRIALS OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) IN COMBINATION WITH HLX87 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING HER2) FOR FIRST-LINE TREATMENT OF HER2-POSITIVE BREAST CANCER (BC) AND NEOADJUVANT TREATMENT FOR HER2-POSITIVE BREAST CANCER (BC NEO) WERE APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (44KB)
Release Time: 07/12/2025 18:24 Stock Code: 02696 Stock Short Name: HENLIUS Document:
Announcements and Notices - [Other - Business Update]
VOLUNTARY ANNOUNCEMENT - INCLUSION OF FUTUONING (FOVINACICLIB CITRATE CAPSULES) IN THE NATIONAL REIMBURSEMENT DRUG LIST (39KB)
Showing 100 of 774 records
Showing 100 of 774 records
Disclaimer

Information contained in the materials available under the web page containing the hyperlink to this disclaimer is posted on this website for the purpose of providing information to the public in Hong Kong. It is not intended as investment advice and must not be relied on as such. It is the sole responsibility of any person who is located outside of Hong Kong to check and comply with all applicable laws and regulations before accessing and using the materials and information.

Please note that the web page contains materials and information provided to HKEX electronically (including information provided in electronic format) by listed issuers, new listing applicants and relevant parties and there is no agency, employee or partner relationship between HKEX and such parties. HKEX does not assume responsibility for screening, editing or monitoring such materials and the information contained in the materials. The information contained in the materials is not verified by HKEX.

HKEX and/or its subsidiaries take no responsibility for the materials and information available under the web page, make no representation as to their accuracy, reliability, completeness or ownership and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information. Some materials may contain hyperlinks to external websites or web pages for which HKEX and/or its subsidiaries are not responsible. (Please see HKEX's "Hyperlink Policy").

Nothing herein shall constitute or be considered to be a limitation upon or a waiver of the privileges and immunities of HKEX and its subsidiaries, which are specifically reserved.

Copyright exists in the information and materials available under the web page and may belong to HKEX, to the author or to any other party depending on the circumstances of publications. Reproduction, distribution, use and/or linking without consent from the relevant parties is not permitted.

If you believe or are aware that any information contained in the materials is inaccurate, erroneous, unlawful, obscene, defamatory or infringes any intellectual property rights of a third party, please contact HKEX e-Submission by email at: ESSHotline@hkex.com.hk.